Condition
Glial Tumor
Total Trials
3
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
33.3%
1 terminated out of 3 trials
Success Rate
0.0%
-86.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results0
Data Visualizations
Phase Distribution
3Total
Not Applicable (2)
P 1 (1)
Trial Status
Recruiting2
Terminated1
Clinical Trials (3)
Showing 3 of 3 trials
NCT05189366Not ApplicableTerminatedPrimary
Sophrology Treatment for Patients With Glial Tumours Requiring Speech Therapy
NCT05139277Not ApplicableRecruiting
Evaluation of the CONVIVO System
NCT04541082Phase 1Recruiting
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Showing all 3 trials